Type 1 Diabetes Researchers Reach Important Milestone

Type 1 Diabetes TrialNet, an international network of researchers exploring ways to prevent and delay the progression of type 1 diabetes, has reached an important milestone: screening 100,000 people to detect who among is at risk of developing type 1 diabetes. This is a major achievement because it has helped researchers better predict who will develop diabetes and when it will require treatment. Earlier diagnosis

Read more

Nova Diabetes Care Announces DECA Sponsorship

Waltham, MA-Nova Diabetes Care, manufacturer of the Nova Max® Plus glucose/ketone meter, announced that it is helping sponsor the Diabetes Education and Camping Association. Established in 1997, DECA serves as the worldwide voice for diabetes camping. The association  provides networking and resources to enhance and expand diabetes camp programs worldwide, and  assists diabetes camp organizations by developing guidelines for diabetes education and management.  DECA also

Read more

FDA OKs Sale of Combo Drug JANUMET

The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC. Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that reduces the production of glucagon, a pancreatic hormone that increases blood glucose levels. Metformin,

Read more

Animas Receives Warning Letter From the FDA

Animas Corporation, a division of Johnson & Johnson that manufactures insulin pumps, has been reprimanded by the FDA for not reporting serious problems resulting from use of its equipment. The parent company was warned that it could face fines and more for selling faulty insulin pumps and failing to disclose serious injuries to diabetic patients who used the OneTouch Ping and 2020 insulin pumps. According

Read more